drugset / Trial / NCT03362619
Engineered Immune Effectors Against Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs). The secondary objectives are to evaluate the rate of successful CC-EIE generation in vitro and determine the anti-CC efficacy.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-EIEs | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | CC-EIEs | Cell therapy | 1e+07 cells/kg | Intravenous |